Effects of Inhaled Corticosteroids, Leukotriene Receptor Antagonists, or Both, Plus Long-Acting ??2-Agonists on Asthma Pathophysiology
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 63 (Supplement) , 35-51
- https://doi.org/10.2165/00003495-200363002-00004
Abstract
Chronic inflammation and smooth muscle dysfunction are consistent features of asthma, and are responsible for disease progression and airway remodelling. The development of chronic airway inflammation depends upon the recruitment and activation of inflammatory cells and the subsequent release of inflammatory mediators, including cytokines. Cellular and histological evaluation of drugs with anti-inflammatory activity, such as inhaled corticosteroids (ICSs), is achieved by analysing samples of lung tissue or biological fluids, obtained by techniques such as bronchial biopsy, bronchoalveolar lavage and sputum induction. These provide valuable information on the inflammatory processes occurring in the lung, although not all are equal in value. The beneficial effects of ICSs in asthma treatment are a consequence of their potent and broad anti-inflammatory properties. Furthermore, there have been promising results indicating that ICSs can reverse some of the structural changes that contribute to airway remodelling. Long-acting β2-agonists (LABAs) added to ICSs provide greater clinical efficacy than ICSs alone, suggesting the possibility of complementary activity on the pathophysiological mechanisms of asthma: inflammation and smooth muscle dysfunction. Leukotrienes play a part in the pathogenesis of asthma. Leukotriene receptor antagonists (LTRAs) directly inhibit bronchoconstriction and may have some antiinflammatory effects, although the extent to which inhibiting one set of inflammatory mediators attenuates the inflammatory response is questionable. In concert with their effect on a broad variety of inflammatory mediators and cells, treatment with ICSs (including ICSs and LABAs) results in superior control of the pathophysiology of asthma and superior clinical efficacy as assessed by the greater improvements in pulmonary function and overall control of asthma compared with LTRAs.Keywords
This publication has 78 references indexed in Scilit:
- Long-Acting ??2-Agonists or Leukotriene Receptor Antagonists as Add-On Therapy to Inhaled Corticosteroids for the Treatment of Persistent AsthmaDrugs, 2003
- Treatment Options for Initial Maintenance Therapy of Persistent AsthmaDrugs, 2003
- A randomized, double‐blind trial of the effect of glucocorticoid, antileukotriene and bβ‐agonist treatment on IL‐10 serum levels in children with asthmaClinical and Experimental Allergy, 2002
- Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trialJournal of Allergy and Clinical Immunology, 2001
- Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthmaThorax, 1999
- The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthmaAnnals of Allergy, Asthma & Immunology, 1999
- Asthma control during long term treatment with regular inhaled salbutamol and salmeterolThorax, 1998
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care.Thorax, 1996
- Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma.Thorax, 1995